Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | IL2 | P60568 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273499 | 0.92 | ALK (0.54) | TNIKALKKITNTRK1MAP4K1 | |
| SCHEMBL15556926 | 0.89 | ALK (0.49) | TNIKALKKITNTRK1MAP4K1 | |
| SCHEMBL15599391 | 0.88 | ALK (0.59) | TNIKALKKITMAP4K1IL2 | |
| SCHEMBL15599469 | 0.88 | ALK (0.69) | TNIKALKKITMAP4K1IL2 | |
| SCHEMBL15599468 | 0.88 | ALK (0.58) | TNIKALKMAP4K1IL2MAP3K11 | |
| SCHEMBL15599271 | 0.85 | ALK (0.56) | ALKKITNTRK1MAP4K1IL2 | |
| SCHEMBL15599359 | 0.85 | ALK (0.56) | TNIKALKMAP4K1IL2MAP3K11 | |
| SCHEMBL15599378 | 0.85 | ALK (0.56) | TNIKALKKITNTRK1MAP4K1 | |
| SCHEMBL15557771 | 0.83 | ALK (0.66) | TNIKALKMAP4K1IL2MAP3K11 | |
| SCHEMBL15599345 | 0.83 | ALK (0.55) | TNIKALKMAP4K1IL2MAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| WO-2014006554-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | TNIK 341/4885ALK 408/4885KIT 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.